Roche (RHHBY.US) has reached a cooperation or investment in the research and development of anti-cancer small molecules worth over 18 billion US dollars.

Recently, Flare Therapeutics announced a strategic discovery partnership with Roche (RHHBY.US). This partnership will utilize Flare Therapeutics' proteomics and mass spectrometry platforms as well as its proprietary library of electrophile compounds to discover novel small molecule drugs targeting transcription factor targets that have not yet been addressed in oncology. As part of the collaboration, Flare Therapeutics will receive a $70 million upfront payment and is eligible for potential milestone payments exceeding $1.8 billion for discovery, development, and commercialization. In the collaboration project, Flare Therapeutics will lead the discovery and preclinical activities targeting multiple transcription factor targets in oncology, while Roche will leverage its expertise in oncology to further the preclinical, clinical development, and commercialization activities of potential products in the collaboration. Flare Therapeutics is a biotechnology company focused on developing transcription factor-targeted drugs. Since its establishment, Flare Therapeutics has rapidly built its emerging pipeline, including its flagship project FX-909, which is an oral small molecule inhibitor targeting PPARG, a potential "first-in-class" drug. PPARG is a key regulator of urothelial carcinoma luminal lineage cells in advanced stages, and FX-909 is currently in phase 1 studies.